| Therapeutic Area | Formulary Choices | Cost for 28 (unless otherwise stated) | Rationale for decision / comments |
|---|---|---|---|
| Thiazides and related diuretics | Indapamide | 2.5mg tablets: £1.08 1.5mg MR tablets: £3.40 (30) | • Hypertension: indapamide 2.5mg daily is considered the optimal dose for hypertension. Low dose indapamide 1.5mg SR has been shown to control hypertension as effectively as 2.5mg (IR) with lower incidence of hypokalaemia. http://www.ncbi.nlm.nih.gov/pubmed/8572850 |
| Bendroflumethiazide | 2.5mg tablets: £0.66 | NB People treated with bendroflumethiazide whose blood pressure is stable & well controlled should continue on bendroflumethiazide • Heart failure: bendroflumethiazide may have a limited role in mild heart failure or where patients are intolerant of loop diuretics. |
|
| Metolazone | 2.5mg tablets 5mg tablets | No longer marketed in UK but remains on formulary for consultant recommendation (Amber drug in the TLG.) | |
| Loop diuretics | Furosemide | 20mg tablets: £1.64 40mg tablets: £2.05 | Furosemide is included in the formulary for use • Heart failure: to provide relief of symptoms. Patients’ who do not respond to 80mg/day will require further specialist advice. • Hypertension: For treatment of resistant hypertension at Step 4 where BP remains sub-optimally controlled despite standard therapies. |
| Aldosterone Antagonists | Spironolactone | 25mg tablets: £1.23 50mg tablets: £4.75 | Spironolactone is included in the formulary for: • Heart failure: second line for specialist initiation in heart failure due to left ventricular systolic dysfunction. Closely monitor potassium and creatinine levels, and eGFR. • Hypertension: For treatment of resistant hypertension at step 4 if blood potassium is ≤ 4.5mmol/l Monitor electrolytes—discontinue if hyperkalaemia occurs (in severe heart failure monitor potassium and creatinine 1 week after initiation and after any dose increase, monthly for first 3 months, then every 3 months for 1 year, and then every 6 months). MHRA alert (Feb 2016) includes the following reminder: •Concomitant use of spironolactone with ACEi or ARB is not routinely recommended because of the risks of severe hyperkalaemia, particularly in patients with marked renal impairment •Use the lowest effective doses of spironolactone and ACEi or ARB if coadministration is considered essential •Regularly monitor serum potassium levels and renal function •Interrupt or discontinue treatment in the event of hyperkalaemia |
| Eplerenone | 25mg tablets: £4.87 50mg tablets: £6.83 | As an alternative to spironolactone, where sex hormone mediated adverse effects experienced when used, in addition to standard therapy, to reduce the risk of cardiovascular mortality and morbidity after recent myocardial infarction in stable patients with left ventricular dysfunction and clinical evidence of heart failure. |
